Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

B2M (Beta-2-microglobulin)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

Tempus xT Assay (1)

oncoReveal™ Core LBx

Tempus xT Assay (1)

oncoReveal™ Core LBx

›

B2M rs1901531	Colorectal Cancer	B2M rs1901531	Colorectal Cancer	cetuximab Sensitive: B - Late Trials cetuximab Sensitive : B	cetuximab Sensitive: B - Late Trials cetuximab Sensitive : B
B2M elevation	Chronic Lymphocytic Leukemia	B2M elevation	Chronic Lymphocytic Leukemia	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3
B2M mutation	Mantle Cell Lymphoma	B2M mutation	Mantle Cell Lymphoma	acalabrutinib Resistant: C3 – Early Trials acalabrutinib Resistant : C3	acalabrutinib Resistant: C3 – Early Trials acalabrutinib Resistant : C3
B2M elevation	Chronic Lymphocytic Leukemia	B2M elevation	Chronic Lymphocytic Leukemia	venetoclax + ibrutinib Sensitive: C3 – Early Trials venetoclax + ibrutinib Sensitive : C3	venetoclax + ibrutinib Sensitive: C3 – Early Trials venetoclax + ibrutinib Sensitive : C3
B2M elevation	Multiple Myeloma	B2M elevation	Multiple Myeloma	Immunomodulator Resistant: C3 – Early Trials Immunomodulator Resistant : C3	Immunomodulator Resistant: C3 – Early Trials Immunomodulator Resistant : C3
B2M elevation	Multiple Myeloma	B2M elevation	Multiple Myeloma	Proteasome inhibitor + Immunomodulator Resistant: C3 – Early Trials Proteasome inhibitor + Immunomodulator Resistant : C3	Proteasome inhibitor + Immunomodulator Resistant: C3 – Early Trials Proteasome inhibitor + Immunomodulator Resistant : C3
B2M elevation	Multiple Myeloma	B2M elevation	Multiple Myeloma	Proteasome inhibitor Resistant: C3 – Early Trials Proteasome inhibitor Resistant : C3	Proteasome inhibitor Resistant: C3 – Early Trials Proteasome inhibitor Resistant : C3
B2M mutation	Hodgkin Lymphoma	B2M mutation	Hodgkin Lymphoma	sintilimab Resistant: C3 – Early Trials sintilimab Resistant : C3	sintilimab Resistant: C3 – Early Trials sintilimab Resistant : C3
B2M mutation + MSI-H/dMMR	Colorectal Cancer	B2M mutation + MSI-H/dMMR	Colorectal Cancer	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
B2M overexpression	Squamous Cell Carcinoma of Head and Neck	B2M overexpression	Squamous Cell Carcinoma of Head and Neck	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
B2M overexpression	Bladder Cancer	B2M overexpression	Bladder Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
B2M elevation	Multiple Myeloma	B2M elevation	Multiple Myeloma	CyBorD Resistant: C3 – Early Trials CyBorD Resistant : C3	CyBorD Resistant: C3 – Early Trials CyBorD Resistant : C3